secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-040946
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Therapeutics Q2 net loss $8.4M; FDA clears 50 mg cohort and OLE trial for CTI-1601 in FA
--------------------------------------------------------------------------------

- Net loss of $8.4M (-$0.19/share) vs $8.7M in Q2 2022; cash $104.2M, runway into Q4 2024.
- FDA cleared initiation of 50 mg cohort in Phase 2 FA trial and Open-Label Extension after review of 25 mg data.
- Top-line data from 25 mg cohort showed CTI-1601 was well-tolerated and increased frataxin levels from baseline.
- New CMO appointed: Russell Clayton, DO, replaces retired Nancy Ruiz.
- Expect top-line 50 mg data in 1H 2024; OLE interim data in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000095017023040946/0000950170-23-040946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000095017023040946/lrmr-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-040946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer